Adebrelimab, famitinib, and irinotecan for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer confirmed by biopsy.
- You have already tried and failed first-line treatment that included chemotherapy and an immunotherapy drug, and you used the immunotherapy for at least 3 months.
- You have at least one tumor that can be measured on scans and has not been treated with radiation (or has grown after radiation).
- Your overall health is good enough for daily activities (ECOG score 0 or 1) and your doctor expects you to live at least 12 more weeks.
- Your blood counts, liver, and kidney function are within specific ranges (your doctor will check these with lab tests).
- You are not pregnant and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (adebrelimab, apatinib, and liposomal irinotecan) for people with advanced gastric or gastroesophageal junction cancer whose first treatment stopped working. The goal is to see if this new combination can help when standard options have failed.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
This trial tests a combination of liposomal irinotecan and albumin-bound paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line chemotherapy. It may be an option if you have already tried a fluorouracil-based treatment.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.